Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 428
- Registration Number
- NCT06376045
- Locations
- 🇨🇱
Centro de Investigacion del Maule, Talca, Chile
🇭🇺Erzsebet Gondozohaz, Godollo, Hungary
🇵🇱Klimed Marek Klimkiewicz, Bialystok, Poland
A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion
- Conditions
- Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
- Interventions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 188
- Registration Number
- NCT06360354
- Locations
- 🇩🇪
Universitaetsklinikum Heidelberg, Heidelberg, Germany
🇩🇪Universitaetsklinikum Wuerzburg, Wuerzburg, Germany
🇬🇷Alexandra Hospital, Athens, Greece
AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
- Conditions
- Thoracic TumorsNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 500
- Registration Number
- NCT06333951
- Locations
- 🇧🇪
Centre Hospitalier Universitaire de Liege - Sart Tilman, Liege, Belgium
🇫🇷Hopital de la Timone, Marseille, France
🇫🇷Institut de Cancerologie de l Ouest Rene Gauducheau, Saint Herblain, France
Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 100
- Registration Number
- NCT06332014
- Locations
- 🇨🇳
Shanghai Sixth Peoples Hospital, Shanghai, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
🇨🇳Beijing Jishuitan Hospital, Beijing, Beijing, China
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 20
- Registration Number
- NCT06321601
- Locations
- 🇵🇱
Dzieciecy Szpital Kliniczny im. Jozefa Polikarpa Brudzinskiego w Warszawie, Warszawa, Poland
🇺🇸Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸University of Minnesota Masonic Childrens Hospital Discovery Clinic, Minneapolis, Minnesota, United States
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
- Conditions
- Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 927
- Registration Number
- NCT06311721
- Locations
- 🇹🇷
Gazi University Faculty of Medicine, Yenimahalle, Ankara, Turkey
🇺🇸Precision NextGen Oncology and Research Center, Beverly Hills, California, United States
🇺🇸TOI Clinical Research, Cerritos, California, United States
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 262
- Registration Number
- NCT06312020
- Locations
- 🇬🇷
Euromedica Kianous Stavros, Thessaloniki, Greece
🇪🇸Hospital Quironsalud Sagrado Corazon, Sevilla, Spain
🇮🇹Fondazione Policlinico Universitario A Gemelli - Rome - PPDS, Roma, Lazio, Italy
A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
- Conditions
- Major Cardiovascular EventEstablished Atherosclerotic Cardiovascular Disease
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 7000
- Registration Number
- NCT06295679
- Locations
- 🇨🇳
The Third Peoples Hospital of Huizhou, Huizhou, Guangdong, China
🇨🇳Zhuhai Peoples Hospital, Zhuhai, Guangdong, China
🇨🇳China Japan Friendship Hospital, Beijing, Beijing, China
A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Rocatinlimab vial injectionCombination Product: Rocatinlimab prefilled syringe
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 240
- Registration Number
- NCT06268860
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc. - Madison, Madison, Wisconsin, United States
🇺🇸Fortrea Clinical Research Unit - Dallas, Dallas, Texas, United States
🇬🇧Fortrea Clinical Research Unit Limited - Leeds, Leeds, LDS, United Kingdom
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 450
- Registration Number
- NCT06252649
- Locations
- 🇺🇸
Ironwood Cancer and Research Centers Scottsdale, Chandler, Arizona, United States
🇺🇸Providence Saint Jude Medical Center, Fullerton, California, United States
🇺🇸Cancer and Blood Specialty Clinic, Los Alamitos, California, United States